US-Russia nuclear treaty expires as warnings grow of new arms race

The New START treaty, signed in 2010, caps deployable U.S. and Russian strategic warheads at 1,550 and delivery systems at 700 and is set to expire on Feb. 5, raising expert warnings that its lapse could open the door to an unfettered nuclear buildup or a new three-way arms race including China. Russia has proposed abiding by the deal for another year if the U.S. does the same, but inspections were suspended during COVID and Moscow paused participation in 2023 amid disputes over U.S. support for Ukraine; the treaty cannot be formally extended a second time, elevating geopolitical risk that could influence defense spending, safe-haven flows and strategic stability considerations for investors.

Analysis

Market structure: Expiration of New START asymmetrically benefits defense primes (LMT, RTX, NOC, GD) and nuclear-related suppliers (BWXT, CCJ, URA ETF) via higher order backlog and pricing power—expect procurement spending to lift revenue run-rates by mid-single digits for primes over 12–36 months and uranium demand shock potential of +20–50% if national programs accelerate. Risk-off flows will transiently bid safe-havens (TLT, GOLD/GLD) and boost volatility; oil upside is conditional on escalation risk, with spikes to >$100/bbl plausible in extreme scenarios.

Risk assessment: Tail risks include kinetic escalation or major sanctions that disrupt global trade chains (low probability, catastrophic) and aggressive three-way arms competition raising CAPEX and input inflation (higher probability over 2–5 years). Immediate (days) impact: equity risk-off, weaker risk-sensitive FX (EM, NOK), stronger USD and gold; short-term (weeks–months): re-rating of defense names and supply-chain scrutiny; long-term (quarters–years): structural revenue growth for selected defense and nuclear sectors but subject to Congressional funding cycles and export-control bottlenecks.

Trade implications: Tactical allocations: overweight mega-primes and selective uranium exposure; pair trades favor long LMT/RTX vs short cyclical industrials or airlines (JETS) to capture safe-haven rotation. Use options to control timing—buy 3–9 month call spreads on LMT/NOC and 6–12 month URA or CCJ exposure; hedge macro with 1–2% portfolio VIX call exposure or GLD calls.

Contrarian angles: Consensus assumes immediate multi-year rearmament; market may be underpricing procurement lag, budget constraints, and verification frictions—primes’ margins could be squeezed by subcontractor inflation and delivery delays. Historical parallels (post-1991 treaty lapses) show multi-year realization, not instant windfalls; be prepared for knee-jerk rallies that fade if diplomatic fixes or voluntary adherence reappear within 30–90 days.

Key Decisions for Investors

• Establish a 2–3% portfolio long split equally between Lockheed Martin (LMT), Raytheon/RTX (RTX), and Northrop Grumman (NOC) within 1–4 weeks; target +20–30% 12–18 month upside, use 15% stop-loss, trim half on +25% gain or on confirmed diplomatic extension within 30–60 days.
• Initiate a 1–2% tactical position in uranium exposure: 0.75–1.25% in CCJ (Cameco) and 0.25–0.75% in URA ETF, hold 12–36 months targeting +40–100% if national civil/military programs accelerate; exit or reduce if nuclear procurement announcements fail to materialize in 6–12 months.
• Open a 1.0–1.5% short position in JETS (airline ETF) or short select travel names to capture immediate risk-off; cover if Brent < $70 for >10 trading days or if VIX drops below 15 and stays there for 10 days.
• Buy options hedges rather than outright duration: purchase 3–9 month call spreads on LMT/NOC (budget ~0.5% portfolio premium each) and a 6–12 month GLD call (0.5% premium) as inflation/geopolitical insurance; reduce options if treaty extension confirmed or if Congressional defense bill fails to pass within 90 days.